RxDoctor Payments Data

Francisco Dubocq Berdeguez, MD

Urology · Bayamon, PRNPI 1487699906

Payments from drug & device makers

$844in general payments, 2019–2025

Across 22 payments — averaging $38.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$348
  • AbbVie$174
  • Olympus Latin America, Inc.$130
  • Pfizer$99
  • Teleflex LLC$50
  • Bayer Puerto Rico Inc.$24
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$66178%
  • Education$18422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)8$348
AbbVie7$174
Olympus Latin America, Inc.1$130
Pfizer3$99
Teleflex LLC1$50
Bayer Puerto Rico Inc.1$24
Neotract Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$844 in reported general payments places this provider in the 30th percentile of 122 urology providers in Puerto Rico.

See all urology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,760
Medicare patients
29
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron125$59,194
PremarinEstrogens, Conjugated26$11,666
Potassium Citrate ErPotassium Citrate83$8,087
ElmironPentosan Polysulfate Sodium11$7,491
Tolterodine Tartrate ErTolterodine Tartrate88$6,212
Tamsulosin Hcl554$4,983
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav166$4,394
Cefadroxil114$2,654
Estradiol18$1,901
Bicalutamide36$984
Levofloxacin66$826
Silodosin19$771
Indapamide65$753
NitrofurantoinNitrofurantoin Macrocrystal23$683
Ciprofloxacin Hcl43$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$99$11,66626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 122 urology providers in Puerto Rico.

Other urology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →